nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Rifampicin—leprosy	0.084	0.548	CbGbCtD
Pimecrolimus—CYP3A4—Dapsone—leprosy	0.0693	0.452	CbGbCtD
Pimecrolimus—Phototoxicity—Dapsone—leprosy	0.0639	0.116	CcSEcCtD
Pimecrolimus—Application site burn—Dapsone—leprosy	0.0585	0.106	CcSEcCtD
Pimecrolimus—MTOR—hindlimb—leprosy	0.0548	0.243	CbGeAlD
Pimecrolimus—Application site erythema—Dapsone—leprosy	0.052	0.0942	CcSEcCtD
Pimecrolimus—Application site pruritus—Dapsone—leprosy	0.0502	0.0909	CcSEcCtD
Pimecrolimus—MTOR—appendage—leprosy	0.047	0.208	CbGeAlD
Pimecrolimus—Application site pain—Dapsone—leprosy	0.0279	0.0505	CcSEcCtD
Pimecrolimus—MTOR—blood vessel—leprosy	0.0262	0.116	CbGeAlD
Pimecrolimus—Application site reaction—Dapsone—leprosy	0.0261	0.0473	CcSEcCtD
Pimecrolimus—Leukaemia—Thalidomide—leprosy	0.0233	0.0422	CcSEcCtD
Pimecrolimus—MTOR—eye—leprosy	0.0139	0.0616	CbGeAlD
Pimecrolimus—FKBP1A—eye—leprosy	0.0125	0.0554	CbGeAlD
Pimecrolimus—MTOR—skin of body—leprosy	0.0121	0.0536	CbGeAlD
Pimecrolimus—Skin exfoliation—Dapsone—leprosy	0.0117	0.0212	CcSEcCtD
Pimecrolimus—FKBP1A—skin of body—leprosy	0.0109	0.0482	CbGeAlD
Pimecrolimus—Toothache—Thalidomide—leprosy	0.0103	0.0187	CcSEcCtD
Pimecrolimus—FKBP1A—Alpha-synuclein signaling—PARK2—leprosy	0.00931	0.136	CbGpPWpGaD
Pimecrolimus—MTOR—tendon—leprosy	0.00923	0.0408	CbGeAlD
Pimecrolimus—FKBP1A—tendon—leprosy	0.0083	0.0367	CbGeAlD
Pimecrolimus—Nasopharyngitis—Dapsone—leprosy	0.00795	0.0144	CcSEcCtD
Pimecrolimus—Influenza—Dapsone—leprosy	0.00769	0.0139	CcSEcCtD
Pimecrolimus—MTOR—testis—leprosy	0.00764	0.0338	CbGeAlD
Pimecrolimus—MTOR—nervous system—leprosy	0.0075	0.0332	CbGeAlD
Pimecrolimus—Acne—Thalidomide—leprosy	0.00745	0.0135	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Dapsone—leprosy	0.00702	0.0127	CcSEcCtD
Pimecrolimus—Viral infection—Thalidomide—leprosy	0.00694	0.0126	CcSEcCtD
Pimecrolimus—Bone disorder—Thalidomide—leprosy	0.00694	0.0126	CcSEcCtD
Pimecrolimus—Skin discolouration—Thalidomide—leprosy	0.00694	0.0126	CcSEcCtD
Pimecrolimus—FKBP1A—testis—leprosy	0.00687	0.0304	CbGeAlD
Pimecrolimus—Herpes simplex—Thalidomide—leprosy	0.00681	0.0123	CcSEcCtD
Pimecrolimus—FKBP1A—nervous system—leprosy	0.00675	0.0298	CbGeAlD
Pimecrolimus—Sinusitis—Dapsone—leprosy	0.00643	0.0116	CcSEcCtD
Pimecrolimus—Pharyngitis—Dapsone—leprosy	0.00611	0.0111	CcSEcCtD
Pimecrolimus—Skin exfoliation—Thalidomide—leprosy	0.00599	0.0108	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.00549	0.0801	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.00537	0.0785	CbGpPWpGaD
Pimecrolimus—Erythema—Dapsone—leprosy	0.00536	0.0097	CcSEcCtD
Pimecrolimus—Gastroenteritis—Thalidomide—leprosy	0.00514	0.0093	CcSEcCtD
Pimecrolimus—MTOR—IL4-mediated signaling events—LTA—leprosy	0.00483	0.0705	CbGpPWpGaD
Pimecrolimus—Dermatitis exfoliative—Thalidomide—leprosy	0.00482	0.00874	CcSEcCtD
Pimecrolimus—Cough—Dapsone—leprosy	0.00467	0.00847	CcSEcCtD
Pimecrolimus—Face oedema—Thalidomide—leprosy	0.0044	0.00796	CcSEcCtD
Pimecrolimus—Breast disorder—Thalidomide—leprosy	0.00411	0.00745	CcSEcCtD
Pimecrolimus—Influenza—Thalidomide—leprosy	0.00393	0.00713	CcSEcCtD
Pimecrolimus—Bronchitis—Thalidomide—leprosy	0.00378	0.00685	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Thalidomide—leprosy	0.00366	0.00662	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Thalidomide—leprosy	0.00359	0.00651	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Dapsone—leprosy	0.00357	0.00647	CcSEcCtD
Pimecrolimus—Pneumonia—Thalidomide—leprosy	0.00353	0.00639	CcSEcCtD
Pimecrolimus—Infestation NOS—Thalidomide—leprosy	0.00351	0.00635	CcSEcCtD
Pimecrolimus—Infestation—Thalidomide—leprosy	0.00351	0.00635	CcSEcCtD
Pimecrolimus—Body temperature increased—Dapsone—leprosy	0.00346	0.00626	CcSEcCtD
Pimecrolimus—Abdominal pain—Dapsone—leprosy	0.00346	0.00626	CcSEcCtD
Pimecrolimus—Conjunctivitis—Thalidomide—leprosy	0.00341	0.00618	CcSEcCtD
Pimecrolimus—Epistaxis—Thalidomide—leprosy	0.00331	0.00599	CcSEcCtD
Pimecrolimus—Sinusitis—Thalidomide—leprosy	0.00329	0.00596	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.00323	0.0471	CbGpPWpGaD
Pimecrolimus—Rhinitis—Thalidomide—leprosy	0.00316	0.00572	CcSEcCtD
Pimecrolimus—Pharyngitis—Thalidomide—leprosy	0.00313	0.00566	CcSEcCtD
Pimecrolimus—Eye disorder—Thalidomide—leprosy	0.00294	0.00533	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.00287	0.0418	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Thalidomide—leprosy	0.00284	0.00515	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Thalidomide—leprosy	0.00284	0.00514	CcSEcCtD
Pimecrolimus—Vomiting—Dapsone—leprosy	0.00278	0.00503	CcSEcCtD
Pimecrolimus—Malnutrition—Thalidomide—leprosy	0.00274	0.00497	CcSEcCtD
Pimecrolimus—Headache—Dapsone—leprosy	0.00274	0.00496	CcSEcCtD
Pimecrolimus—Back pain—Thalidomide—leprosy	0.00265	0.0048	CcSEcCtD
Pimecrolimus—Nausea—Dapsone—leprosy	0.0026	0.0047	CcSEcCtD
Pimecrolimus—Angioedema—Thalidomide—leprosy	0.00251	0.00454	CcSEcCtD
Pimecrolimus—Cough—Thalidomide—leprosy	0.00239	0.00433	CcSEcCtD
Pimecrolimus—Arthralgia—Thalidomide—leprosy	0.00233	0.00423	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00232	0.0042	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—RIPK2—leprosy	0.00225	0.0329	CbGpPWpGaD
Pimecrolimus—Oedema—Thalidomide—leprosy	0.00224	0.00405	CcSEcCtD
Pimecrolimus—Infection—Thalidomide—leprosy	0.00222	0.00403	CcSEcCtD
Pimecrolimus—CYP3A4—nervous system—leprosy	0.0022	0.00975	CbGeAlD
Pimecrolimus—Nervous system disorder—Thalidomide—leprosy	0.00219	0.00397	CcSEcCtD
Pimecrolimus—Skin disorder—Thalidomide—leprosy	0.00217	0.00394	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Thalidomide—leprosy	0.00204	0.00369	CcSEcCtD
Pimecrolimus—Paraesthesia—Thalidomide—leprosy	0.00201	0.00364	CcSEcCtD
Pimecrolimus—Dyspnoea—Thalidomide—leprosy	0.00199	0.00361	CcSEcCtD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—leprosy	0.00196	0.0286	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Thalidomide—leprosy	0.00193	0.0035	CcSEcCtD
Pimecrolimus—Pain—Thalidomide—leprosy	0.00191	0.00347	CcSEcCtD
Pimecrolimus—Constipation—Thalidomide—leprosy	0.00191	0.00347	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Thalidomide—leprosy	0.00183	0.00331	CcSEcCtD
Pimecrolimus—Urticaria—Thalidomide—leprosy	0.00178	0.00322	CcSEcCtD
Pimecrolimus—Abdominal pain—Thalidomide—leprosy	0.00177	0.0032	CcSEcCtD
Pimecrolimus—Body temperature increased—Thalidomide—leprosy	0.00177	0.0032	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD8A—leprosy	0.00171	0.0249	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL10—leprosy	0.00168	0.0245	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—CD40LG—leprosy	0.00168	0.0245	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Thalidomide—leprosy	0.00165	0.00299	CcSEcCtD
Pimecrolimus—Pruritus—Thalidomide—leprosy	0.00158	0.00287	CcSEcCtD
Pimecrolimus—Diarrhoea—Thalidomide—leprosy	0.00153	0.00277	CcSEcCtD
Pimecrolimus—MTOR—Type II diabetes mellitus—TNF—leprosy	0.00146	0.0214	CbGpPWpGaD
Pimecrolimus—Vomiting—Thalidomide—leprosy	0.00142	0.00258	CcSEcCtD
Pimecrolimus—Rash—Thalidomide—leprosy	0.00141	0.00256	CcSEcCtD
Pimecrolimus—Dermatitis—Thalidomide—leprosy	0.00141	0.00255	CcSEcCtD
Pimecrolimus—Headache—Thalidomide—leprosy	0.0014	0.00254	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—HLA-DRB1—leprosy	0.00139	0.0203	CbGpPWpGaD
Pimecrolimus—Nausea—Thalidomide—leprosy	0.00133	0.00241	CcSEcCtD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—leprosy	0.00133	0.0194	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—IFNG—leprosy	0.00132	0.0193	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—leprosy	0.00127	0.0185	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—HLA-DRB1—leprosy	0.00126	0.0183	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—HLA-DRB1—leprosy	0.00106	0.0155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IFNG—leprosy	0.00105	0.0153	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IFNG—leprosy	0.00101	0.0148	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—leprosy	0.000979	0.0143	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL2—leprosy	0.000933	0.0136	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—IFNG—leprosy	0.000918	0.0134	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL2—leprosy	0.000901	0.0132	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—leprosy	0.000886	0.0129	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—IL2—leprosy	0.000815	0.0119	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—leprosy	0.000748	0.0109	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—leprosy	0.000704	0.0103	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—leprosy	0.000679	0.00992	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000648	0.00946	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—RIPK2—leprosy	0.000645	0.00942	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CYLD—leprosy	0.000571	0.00834	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000501	0.00732	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PARK2—leprosy	0.000485	0.00708	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SLC11A1—leprosy	0.000483	0.00705	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—leprosy	0.000462	0.00675	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RIPK2—leprosy	0.000368	0.00537	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—TLR2—leprosy	0.000368	0.00537	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RIPK2—leprosy	0.000353	0.00516	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NOD2—leprosy	0.000334	0.00487	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CYLD—leprosy	0.000333	0.00486	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PARK2—leprosy	0.000294	0.00429	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SLC11A1—leprosy	0.000271	0.00396	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40LG—leprosy	0.000271	0.00395	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—leprosy	0.000268	0.00391	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RIPK2—leprosy	0.000246	0.0036	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-DRB1—leprosy	0.000218	0.00318	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RIPK2—leprosy	0.000214	0.00313	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—TLR2—leprosy	0.000214	0.00313	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NOD2—leprosy	0.000194	0.00284	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—leprosy	0.000164	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—leprosy	0.000162	0.00237	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—leprosy	0.00016	0.00234	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—leprosy	0.000154	0.00225	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—leprosy	0.000153	0.00224	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RIPK2—leprosy	0.000139	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-DRB1—leprosy	0.000132	0.00193	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—leprosy	9.87e-05	0.00144	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—leprosy	9.66e-05	0.00141	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—leprosy	9.33e-05	0.00136	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—leprosy	8.61e-05	0.00126	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—leprosy	8.58e-05	0.00125	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SDHD—leprosy	8.02e-05	0.00117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—leprosy	5.55e-05	0.00081	CbGpPWpGaD
